FDA Begins Reviewing Henlius’ Trastuzumab
The Oncology Biosimilar Is Already Approved In China And The EU
The US FDA has accepted a BLA for Henlius’ trastuzumab biosimilar candidate HLX02, marking another step in the Chinese company’s push for the US oncology market
